Mark Meltz

Mark joined us from Audentes Therapeutics where he was Senior Vice President and General Counsel and helped lead its sale to Astellas Pharma. Prior to joining Audentes, he was Executive Vice President and Chief Business Development and Legal Officer at PaxVax where he led the company’s Legal, Compliance, Government Affairs and Business Development functions and helped lead its sale to Emergent BioSolutions. Mark also held senior legal positions at Biogen and Novartis Vaccines and Diagnostics, and served as Counsel at the global law firm Bingham McCutchen (now part of Morgan Lewis), where his work focused on mergers and acquisitions, venture capital financing, securities regulation and general corporate matters. Mark holds a BA from Yale University and a JD from Boston College Law School.